A Controlled Trial of Cyclosporine as a Chemotherapy- Resistance Modifier in High Risk Acute Myeloid Leukemia, Phase III
Publication Information Expand/Collapse
PMid: PMID28586789; PMC5710507
PMid: PMID25527568 | PMC number: PMC4349271
PMid: PMID24383844 | PMC number: PMC4117470
PMid: PMID23760400 | PMC number: PMC4457325
PMid: PMID23967110 | PMC number: PMC3743845
PMid: PMID21928314 | PMC number: PMC3490403
PMid: PMID22315487 | PMC number: PMCID3436242
Expression of topoisomerase II isoforms a and B in adult patients with acute myeloid leukemia (AML): relationship to immunophenotype and treatment outcome
Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype [PMID21330329; PMC3069244]
Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation [PMID21680797;PMC3156042]
Cytarabine dose for acute myeloid leukemia. (Letter to the Editor) [PMID21631340]
Prediction of early death following induction therapy for newly diagnosed acute leukemia with pretreatment risk scores: a novel paradigm for treatment assignment
PMid: PMID21969499 | PMC number: PMC3221524
The effect of complete remission (CR) and CR with incomplete platelet recovery (CRp) on outcome in acute myeloid leukemia: a combined eastern cooperative oncology group (ECOG), Southwest Oncology Group (SWOG), and M.D. Anderson Cancer Center study
PMid: PMID20562328 | PMC number: PMC3709629
Over-expression of novel IRF8 splice variants is associated with a significant decrease in relapse-free survival in adult AML patients
Influence of residual normal metaphases in patients with monosomal karyotype
Very late antigen-4 (VLA-4) function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia [PMC2630271; PMID18927435]
The Southwest Oncology Group: progress in cancer research [PMID18929152]
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia. a Southwest Oncology Group study
Microsatellite Instability is not a defining genetic feature of acute myeloid leukemogenesis in adults: results of a retrospective study of 132 patients and review of the literature
Benefit of cycloporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) study.
Trisomy 10 as the sole cytogenetic abnormality in hematologic neoplasia.
Functional assessment of the multidrug (MDR1) resistance efflux pump in acute myeloid leukemia (AML): Identification of CD34-, CD33+, MRK16+ (MDR1+) cases lacking functional dye efflux.
Multidrug resistance: clinical relevance in acute leukemia